These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30115104)

  • 1. Partial factorial trials: comparing methods for statistical analysis and economic evaluation.
    Dakin HA; Gray AM; MacLennan GS; Morris RW; Murray DW
    Trials; 2018 Aug; 19(1):442. PubMed ID: 30115104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of factorial randomised controlled trials: challenges, methods and recommendations.
    Dakin H; Gray A
    Stat Med; 2017 Aug; 36(18):2814-2830. PubMed ID: 28470760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local anaesthetic wound infiltration in addition to standard anaesthetic regimen in total hip and knee replacement: long-term cost-effectiveness analyses alongside the APEX randomised controlled trials.
    Marques EM; Blom AW; Lenguerrand E; Wylde V; Noble SM
    BMC Med; 2015 Jun; 13():151. PubMed ID: 26116078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patellofemoral arthroplasty is cheaper and more effective in the short term than total knee arthroplasty for isolated patellofemoral osteoarthritis: cost-effectiveness analysis based on a randomized trial.
    Fredborg C; Odgaard A; Sørensen J
    Bone Joint J; 2020 Apr; 102-B(4):449-457. PubMed ID: 32228074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COmmunity-based Rehabilitation after Knee Arthroplasty (CORKA): study protocol for a randomised controlled trial.
    Barker KL; Beard D; Price A; Toye F; Underwood M; Drummond A; Collins G; Dutton S; Campbell H; Kenealy N; Room J; Lamb SE
    Trials; 2016 Oct; 17(1):501. PubMed ID: 27737685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a practical approach to expert elicitation for randomised controlled trials with missing health outcomes: Application to the IMPROVE trial.
    Mason AJ; Gomes M; Grieve R; Ulug P; Powell JT; Carpenter J
    Clin Trials; 2017 Aug; 14(4):357-367. PubMed ID: 28675302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Evaluation of Factorial Trials: Cost-Utility Analysis of the Atorvastatin in Factorial With Omega EE90 Risk Reduction in Diabetes 2 × 2 × 2 Factorial Trial of Atorvastatin, Omega-3 Fish Oil, and Action Planning.
    Dakin HA; Farmer A; Gray AM; Holman RR
    Value Health; 2020 Oct; 23(10):1340-1348. PubMed ID: 33032778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter?
    Hollingworth W; McKell-Redwood D; Hampson L; Metcalfe C
    Clin Trials; 2013 Feb; 10(1):43-53. PubMed ID: 23231969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.
    Groot Koerkamp B; Spronk S; Stijnen T; Hunink MG
    Value Health; 2010; 13(2):242-50. PubMed ID: 19818058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision aids for patients considering total joint replacement: a cost-effectiveness analysis alongside a randomised controlled trial.
    Trenaman L; Stacey D; Bryan S; Taljaard M; Hawker G; Dervin G; Tugwell P; Bansback N
    Osteoarthritis Cartilage; 2017 Oct; 25(10):1615-1622. PubMed ID: 28624294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which interactions matter in economic evaluations? A systematic review and simulation study.
    Dakin H; Gray A
    BMC Med Res Methodol; 2020 May; 20(1):109. PubMed ID: 32380948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.
    Wilby J; Kainth A; Hawkins N; Epstein D; McIntosh H; McDaid C; Mason A; Golder S; O'Meara S; Sculpher M; Drummond M; Forbes C
    Health Technol Assess; 2005 Apr; 9(15):1-157, iii-iv. PubMed ID: 15842952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative outcomes and cost-utility following surgical treatment of focal lumbar spinal stenosis compared with osteoarthritis of the hip or knee: part 2--estimated lifetime incremental cost-utility ratios.
    Rampersaud YR; Tso P; Walker KR; Lewis SJ; Davey JR; Mahomed NN; Coyte PC
    Spine J; 2014 Feb; 14(2):244-54. PubMed ID: 24239803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for economic evaluation alongside a multicentre trial in developing countries: a case study from the WHO Antenatal Care Randomised Controlled Trial.
    Mugford M; Hutton G; Fox-Rushby J
    Paediatr Perinat Epidemiol; 1998 Oct; 12 Suppl 2():75-97. PubMed ID: 9805724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.